Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹249 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹96 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Clean Science reported a resilient Q4 FY26 with consolidated revenue of ₹246 crore (+14% QoQ) and EBITDA margin of 33%. Standalone revenue grew 8% QoQ to ₹193 crore, driven by volume recovery in flagship products. The health subsidiary achieved its first positive EBITDA of ₹7 crore, with volumes exceeding 1,000 tons and blended realizations improving to ₹460/kg. Management highlighted persistent pricing pressure from Chinese competition in MEHQ and anisol, but noted improved gross margins due to product mix. FY27 guidance remains cautious due to geopolitical uncertainty and crude price volatility. Key risks include inability to fully pass on raw material cost increases and potential oversupply from new domestic entrants.
Colored figures show movement against the previous available record.
Guidance to track
- The new plant for water treatment chemicals is expected to be commercialized by September 2026, with validation in Q3 and revenue contribution from Q4 FY27.
- Management guided a capex range of ₹80-100 crore for the upcoming fiscal year, primarily for debottlenecking and backward integration.
- Backward integration into key intermediates for health products is expected to improve margins and reduce import dependence, though no specific target was given.
Risks flagged
- China's access to cheaper crude oil allows Chinese producers to offer lower prices for phenol and acetone, creating an arbitrage that pressures Clean Science's margins.
- Long-term contracts prevent immediate pass-through of higher phenol and acetone costs, with renegotiation only possible upon contract expiry.
- Companies like Vinati Organics and Gem Aromatics are entering with large capacities, potentially leading to oversupply and margin compression.
Key quotes
- We are waiting for this Chinese summit to end then this Russian Putin Chinese again summit to end to understand where the world stands in terms of crude oil.
- We have maintained the market share by responding to the competition but still in percentage terms the gross margin has increased.
- This is going to be a very tricky financial year for chemical industry in my view.
Research modules